News & events
News
Stefan Bröer is looking for the right molecule for a biological target, that could be developed into a drug to treat diabetes. Now ANU has its own library of compounds, available to biological and medical researchers, managed by the Research School of Chemistry.
Aude Fahrer's work aims to activate the immune cells responsible for attacking cancer, in a simple, low cost way.
Alex Maier has been elected as a Fellow of the Australian Society for Parasitology.
They say leaders are born not made, but it seems the opposite is true for queen bees, according to a new study by researchers from The Australian National University (ANU) and Queen Mary University of London.
New research from The Australian National University (ANU) has drilled down to the molecular level to find similarities across six pharmaceutical drugs used in pain relief, dentist anaesthetic, and treatment of epilepsy, in a bid to find a way to reduce unwanted side-effects.
Linden Muellner-Wong has won a 2017 RSB Director's Prize in Honours.
Events
Throughout my PhD, I determined the transport mechanisms of two proteins that we show break the standard channel / transporter definitions and instead function as anion “chansporters” - proteins that exist somewhere on the spectrum between transporters and channels.
BSB Seminar Series: Structural Basis of Heteromeric Amino Acid Transporters for Targeted Drug Design
Heteromeric amino acid transporters (HATs) play essential roles in the transport of amino acids, thyroid hormones, and various amino acid–like drugs. Mutations in HATs are associated with several inherited disorders, including cystinuria, lysinuric protein intolerance, and autism spectrum disorders.
Autotransporters (ATs) are virulence factors found in Gram-negative bacteria that consist of three domains: an N-terminal signal peptide, a central passenger domain, and a C-terminal β-barrel domain. Here, we used RpeA from rabbit enteropathogenic Escherichia coli as a model AT.
The ability of Plasmodium falciparum to access and utilise vital nutrients, including riboflavin (vitamin B2), is essential for its growth and proliferation, positioning riboflavin metabolism as a promising target for antimalarial intervention.
My work studies how platelets control malarial infection, and through this has revealed the specific anti-plasmodial actions of platelets and molecules with novel mechanisms of parasite killing.
Leveraging artificial intelligence and deep learning to generate proteins de novo has unlocked new frontiers of protein design. This approach can be used to design bespoke binders that target specific proteins and domains.